Novartis | NVS - PE Price to Earnings


Novartis reported 17.79 in PE Price to Earnings for its fiscal quarter ending in December of 2025.





Pe Change Date
AbbVie 23.03 1 Mar/2026
Amgen 19.84 5.47 Mar/2026
AstraZeneca 29.59 2.3 Mar/2026
Bausch Health Companies 6.98 0.41 Dec/2025
Biogen 13.7 0.32 Mar/2026
Bristol-Myers Squibb 9.08 0.2 Mar/2026
Corcept Therapeutics 113.58 71.67 Mar/2026
Drreddys Laboratories 18.27 0.84 Dec/2025
Eli Lilly 40.27 0.06 Mar/2026
Gilead Sciences 17.7 2.07 Mar/2026
GlaxoSmithKline 14.87 3.72 Mar/2026
Glaxosmithkline 11.66 0.28 Dec/2025
J&J 24.53 0.91 Mar/2026
Merck 16.52 2.6 Mar/2026
Novartis 20.17 2.32 Mar/2026
Novartis 17.79 1.74 Dec/2025
Pacira 38.58 14.1 Mar/2026
Perrigo 27.45 31.51 Mar/2026
Pfizer 9.32 5.16 Mar/2026
Phibro Animal Health 13.82 4.04 Dec/2025
Prestige Brands 15.31 3.1 Dec/2025
Roche Holding 16.09 3.51 Dec/2025
Sanofi 11.84 0.14 Mar/2026
Sanofi 15.75 1.53 Dec/2025
Supernus Pharmaceuticals 44.21 66.17 Mar/2026
Zoetis 18.8 1.62 Mar/2026